These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 16056005)

  • 21. How to use structured decision making in developing therapeutic, cost-effective formulary systems.
    Crane VS
    Hosp Formul; 1993 Oct; 28(10):859-62, 865-7. PubMed ID: 10129135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The case for a value-based formulary: striving for total lowest net cost.
    Weart W; Bauman GR
    Manag Care Interface; 2007 Apr; 20(4):42-7. PubMed ID: 17474330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Using cost-effectiveness analysis to sharpen formulary decision-making: the example of tiotropium at the Veterans Affairs health care system.
    Onukwugha E; Mullins CD; DeLisle S
    Value Health; 2008; 11(5):980-8. PubMed ID: 18194405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strategies for success in creating an effective multihospital health-system pharmacy and therapeutics committee.
    Leonard MC; Thyagarajan R; Wilson AJ; Sekeres MA
    Am J Health Syst Pharm; 2018 Apr; 75(7):451-455. PubMed ID: 29572313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions.
    Lipsy RJ
    Pharmacoeconomics; 1992 Apr; 1(4):265-81. PubMed ID: 10147017
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions.
    Grabowski H; Mullins CD
    Soc Sci Med; 1997 Aug; 45(4):535-44. PubMed ID: 9226779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacoeconomics and formulary decision making.
    Sanchez LA
    Pharmacoeconomics; 1996; 9 Suppl 1():16-25. PubMed ID: 10160112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of pharmacoeconomic data in formulary selection.
    Hatoum HT; Freeman RA
    Top Hosp Pharm Manage; 1994 Jan; 13(4):47-53. PubMed ID: 10130683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
    Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of the Level of Satisfaction and Unmet Data Needs for Specialty Drug Formulary Decisions in the United States.
    Choi Y; Navarro RP
    J Manag Care Spec Pharm; 2016 Apr; 22(4):368-75. PubMed ID: 27023690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adoption of a new technology in a Veterans Affairs national formulary system with local implementation: the insulin glargine example.
    Barengolts EI; Burke BV; Duckworth WC; Kaminsky R; Miller DR; Swislocki AL
    Manag Care Interface; 2007 Mar; 20(3):37-44, 57. PubMed ID: 17458480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacy formularies in integrated health systems.
    Osborne JA
    J Healthc Resour Manag; 1997; 15(1):18-20. PubMed ID: 10164678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The formulary decision-making process in a US academic medical centre.
    Nash DB; Catalano ML; Wordell CJ
    Pharmacoeconomics; 1993 Jan; 3(1):22-35. PubMed ID: 10146985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Using pharmacoeconomic analysis to make drug insurance coverage decisions.
    Anis AH; Rahman T; Schechter MT
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 2):119-26. PubMed ID: 10176146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Formularies, therapeutics, and outcomes: new opportunities.
    Fullerton DS; Atherly DS
    Med Care; 2004 Apr; 42(4 Suppl):III39-44. PubMed ID: 15026670
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacoeconomic series: Part 3. Applying pharmacoeconomic and quality-of-life measures to the formulary management process.
    Skaer TL
    Hosp Formul; 1993 Jun; 28(6):577-84. PubMed ID: 10126586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Using cost-effectiveness analysis for formulary decision making: from theory into practice.
    Detsky AS
    Pharmacoeconomics; 1994 Oct; 6(4):281-8. PubMed ID: 10147465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis and the formulary decision-making process.
    Wang Z; Salmon JW; Walton SM
    J Manag Care Pharm; 2004; 10(1):48-59. PubMed ID: 14720105
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Effect Of Veterans Health Administration Coverage On Cost-Related Medication Nonadherence.
    Gaffney A; Bor DH; Himmelstein DU; Woolhandler S; McCormick D
    Health Aff (Millwood); 2020 Jan; 39(1):33-40. PubMed ID: 31905070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.